Eugia Pharma receives USFDA Approval for Dasatinib Tablets
The company has a market cap of over Rs 70,000 crore and the stock is up by 23 per cent from its 52-week low of Rs 994.35 per share.
Aurobindo Pharma Limited declared that Eugia Pharma Specialities Limited which operates as its wholly owned subsidiary, received USFDA approval to distribute Dasatinib Tablets across different dosage levels. Aurobindo Pharma developed this product which demonstrates both bioequivalence and therapeutic equivalence to Sprycel Tablets produced by Bristol-Myers Squibb Company. The pharmaceutical product targets Philadelphia chromosome-positive chronic myeloid leukaemia and acute lymphoblastic leukaemia during multiple stages of development and the company will launch it during FY26 Q1. IQVIA MAT shows the product market size reaches US$ 1.8 billion for the twelve months ending February 2025. The 181st ANDA approval from Eugia Pharma Specialities Group has been achieved by their oncology oral and sterile speciality product manufacturing operations. Aurobindo Pharma, based in Hyderabad, India, operates as a global pharmaceutical enterprise that develops, manufactures and distributes both generic and branded speciality pharmaceuticals and active pharmaceutical ingredients across 150 countries.
Aurobindo Pharma serves as India's major pharmaceutical business which stands as the nation's second-largest listed pharmaceutical company by revenue, while maintaining its position as the leading generic pharmaceutical company in the US market. The company operates in two main business segments: Formulations and Active Pharmaceutical Ingredients (API). Formulations represented 87 per cent of the total business in Q3 FY25 because the company concentrated on major therapeutic areas like CNS, Anti-Retroviral, CVS and additional categories. The API segment contributed 13 per cent to the business with a dual beta-lactams and non-beta-lactams presence.
DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, download the service details here.
The company exports products to more than 150 nations, where international markets provide 90 per cent of its business revenue. The company maintains 29 worldwide manufacturing facilities alongside a scientific research department comprising more than 1500 experts. Under the PLI scheme, the company opened a new Penicillin-G production facility and increased R&D spending to 5.6 per cent of sales during Q3 FY25. The company has submitted 853 US ANDAs and 4,535 formulation dossiers for advanced markets through their global regulatory filing process.
The company has a market cap of over Rs 70,000 crore and the stock is up by 23 per cent from its 52-week low of Rs 994.35 per share. Investors should keep an eye on this mid-cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.